Overview
Monika Richter focuses her practice on the biotechnology and pharmaceuticals sector. She advises national and international clients on various legal matters related to the development and partnering of pharmaceutical compounds and products, with a particular focus on strategic alliances, license agreements, research collaborations and co-development agreements. Her work likewise includes financing and corporate transactions as well as mergers and acquisitions.
Given her Polish background, Monika is active in the Eastern European market, regularly speaking at industry conferences in Poland and advising Polish clients on several cross-border collaborations in the life sciences sector.
Prior to joining McDermott, Monika has worked for other international law firms in Berlin and Frankfurt.
Results
- Advised REGENXBIO on co-development and licensing partnership with AbbVie for development of RGX-314, a potential one-time gene therapy for retinal diseases
- Advised STADA on exclusive licensing transaction with Calliditas for commercialization of novel specialty drug for treatment of chronic autoimmune kidney disease
- Advised Merck on out-licensing transaction with Diaccurate for development of clinical stage cancer therapy candidate and on various other collaboration agreements
- Advised Merck on co-development and licensing partnership with Neuroloop (B. Braun start-up) for the development of neurostimulator device for treatment of chronic inflammatory diseases
- Advised Biogen Inc. on various in-licensing collaborations, including Reborna (Takeda spin-out), Cevec, iSD
- Advised Treeway on out-licensing transaction with Ferrer for development of compound for treatment of ALS and other neurodegenerative diseases
- Advised Paion on various licensing agreements with local partners, including Mundipharma and TTY, as well as on various distribution and manufacturing and supply agreements regarding its market ready anesthesiologic product Remimazolam and other products
- Advised Adamed on out-licensing transaction with Acadia on early stage compound
- Advised OncoArendi on out-licensing transaction with Galapagos for development of clinical stage candidate for treatment of fibrotic diseases
- Advised Selvita, one of Poland’s largest biotechnology companies, on various international licensing and collaboration agreements, including with Orion Pharma, H3, Felicitex, Merck KGaA, Menarini and on a funding agreement with the Leukemia and Lymphoma Society*
- Advised a big Polish pharmaceutical company on a research collaboration with a German pharmaceutical company*
- Advised uniQure on a commercialization agreement for Glybera, the first gene therapy product approved in the EU, with Chiesi and on an exclusive strategic collaboration with Bristol-Myers Squibb*
- Advised several biotechnology companies on multinational bidder transactions directed to licensing agreements with local partners, most recently a US pharmaceutical company on a multinational licensing transaction regarding local rights for a dermatological assets with partners in China, Japan, India and US*
- Advised several biotechnology companies on research and collaboration agreements and IP transfer agreements with universities/university clinics in Germany and other countries of the world*
*Matter handled prior to joining McDermott
Recognitions
- Legal 500 EMEA 2022: “Monika Richter: Forward-looking, prudent, razor-sharp when it comes to implementing client interests.”; „The team around Monika Richter and Deniz Tschammler offers an exceptional combination of industry expertise in the healthcare sector and deal experience.“
- Handelsblatt/Best Lawyers 2022 Germany: Leading Lawyer for Biotechnology Law and Life Sciences Practice
- Handelsblatt/Best Lawyers 2021 Germany: Leading Lawyer for Biotechnology Law and Life Sciences Practice
- Leaders League’ 2019 Guide, Innovation, Technology & Patents: “Excellent” in the Health, pharma & biotechnology category
